The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Passage Bio Inc shares valued at $30,372 were sold by ORBIMED ADVISORS LLC on Apr 23 ’25. At $0.34 per share, ORBIMED ADVISORS LLC sold 89,328 shares. The insider’s holdings dropped to 6,718,195 shares worth approximately $3.02 million following the completion of this transaction.
Also, ORBIMED ADVISORS LLC sold 78,049 shares, netting a total of over 26,537 in proceeds. Following the sale of shares at $0.34 each, the insider now holds 6,807,523 shares.
Before that, ORBIMED ADVISORS LLC had sold 68,195 shares from its account. In a trade valued at $21,822, the 10% Owner traded Passage Bio Inc shares for $0.32 each. Upon closing the transaction, the insider’s holdings decreased to 68,195 shares, worth approximately $2.99 million.
Analysts at Rodman & Renshaw started covering the stock with ‘”a Buy”‘ outlook in a report released in early September. As of March 08, 2022, JP Morgan has decreased its “an Overweight” rating to a “Neutral” for PASG. Earlier on January 19, 2022, Goldman downgraded its rating. Their new recommendation was “a Neutral” for PASG stock which previously was a “a Buy”.
Analyzing PASG Stock Performance
During the last five days, there has been a surge of approximately 50.07%. Over the course of the year, Passage Bio Inc shares have dropped approximately -20.35%. Shares of the company reached a 52-week high of $1.0100 on 01/02/25 and a 52-week low of $0.2570 on 05/14/25.
Support And Resistance Levels for Passage Bio Inc (PASG)
According to the 24-hour chart, there is a support level at 0.3845, which, if violated, would cause prices to drop to 0.3172. In the upper region, resistance lies at 0.4945. The next price resistance is at 0.5372. RSI (Relative Strength Index) is 67.21 on the 14-day chart, showing neutral technical sentiment.
